Live bacterial vaccine vectors: An overview

Silva, A. J. da; Zangirolami, Teresa Cristina; Novo-Mansur, Maria Teresa Marques; Giordano, Roberto de Campos; Martins, Elizabeth A. L.

doi:10.1590/s1517-83822014000400001

Cited by 75 publications

(58 citation statements)

References 132 publications

(138 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Salmonella enterica serovar Typhimurium ( S. typhimurium ) is an important intracellular pathogen, causing acute gastroenteritis in humans and many other mammalian species . However, attenuated strains of this bacterium have been investigated to develop several biotechnological products . Amongst these products, promising results have been obtained for potential vaccine delivery systems for foreign antigens against a diversity of infectious agents, including bacteria (such as Helicobacter pylori, Salmonella enterica serotype Typhi and Streptococcus pneumoniae ), viruses (HIV and influenza), parasitic pathogens, and cancer .…”

Section: Introductionmentioning

confidence: 99%

“…Amongst these products, promising results have been obtained for potential vaccine delivery systems for foreign antigens against a diversity of infectious agents, including bacteria (such as Helicobacter pylori, Salmonella enterica serotype Typhi and Streptococcus pneumoniae ), viruses (HIV and influenza), parasitic pathogens, and cancer . Hence, S. typhimurium is a microorganism with significance in both medicine and biotechnology, and has been studied extensively in the areas of genetics and immunology . In last years, several studies have been published regarding S. enterica metabolism regulation .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salmonella typhimuriumandEscherichia colidissimilarity: Closely related bacteria with distinct metabolic profiles

Sargo

Campani

Silva

et al. 2015

Biotechnol Progress

View full text Add to dashboard Cite

Live attenuated strains of Salmonella typhimurium have been extensively investigated as vaccines for a number of infectious diseases. However, there is still little information available concerning aspects of their metabolism. S. typhimurium and Escherichia coli show a high degree of similarity in terms of their genome contents and metabolic networks. However, this work presents experimental evidence showing that significant differences exist in their abilities to direct carbon fluxes to biomass and energy production. It is important to study the metabolism of Salmonella to elucidate the formation of acetate and other metabolites involved in optimizing the production of biomass, essential for the development of recombinant vaccines. The metabolism of Salmonella under aerobic conditions was assessed using continuous cultures performed at dilution rates ranging from 0.1 to 0.67 h(-1), with glucose as main substrate. Acetate assimilation and glucose metabolism under anaerobic conditions were also investigated using batch cultures. Chemostat cultivations showed deviation of carbon towards acetate formation, starting at dilution rates above 0.1 h(-1). This differed from previous findings for E. coli, where acetate accumulation was only detected at dilution rates exceeding 0.4 h(-1), and was due to the lower rate of acetate assimilation by S. typhimurium under aerobic conditions. Under anaerobic conditions, both microorganisms mainly produced ethanol, acetate, and formate. A genome-scale metabolic model, reconstructed for Salmonella based on an E. coli model, provided a poor description of the mixed fermentation pattern observed during Salmonella cultures, reinforcing the different patterns of carbon utilization exhibited by these closely related bacteria.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Salmonella typhimuriumandEscherichia colidissimilarity: Closely related bacteria with distinct metabolic profiles

Sargo

Campani

Silva

et al. 2015

Biotechnol Progress

View full text Add to dashboard Cite

show abstract

“…The primary limitation of bacterial vectors is their lack of immunogenicity compared with viral vectors [68]. Furthermore there are several other limitations to overcome.…”

Section: Discussionmentioning

confidence: 99%

Vector-based genetically modified vaccines: Exploiting Jenner’s legacy

Ramezanpour

Haan

Osterhaus

et al. 2016

Vaccine

View full text Add to dashboard Cite

The global vaccine market is diverse while facing a plethora of novel developments. Genetic modification (GM) techniques facilitate the design of 'smarter' vaccines. For many of the major infectious diseases of humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vaccines are available. It may be speculated that novel GM technologies will significantly contribute to their development. While a promising number of studies is conducted on GM vaccines and GM vaccine technologies, the contribution of GM technology to newly introduced vaccines on the market is disappointingly limited. In this study, the field of vector-based GM vaccines is explored. Data on currently available, actually applied, and newly developed vectors is retrieved from various sources, synthesised and analysed, in order to provide an overview on the use of vector-based technology in the field of GM vaccine development. While still there are only two vector-based vaccines on the human vaccine market, there is ample activity in the fields of patenting, preclinical research, and different stages of clinical research. Results of this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipeline. This study further highlights that poxviruses and adenoviruses are among the most prominent vectors in GM vaccine development. After the approval of the first vectored human vaccine, based on a flavivirus vector, vaccine vector technology, especially based on poxviruses and adenoviruses, holds great promise for future vaccine development. It may lead to cheaper methods for the production of safe vaccines against diseases for which no or less perfect vaccines exist today, thus catering for an unmet medical need. After the introduction of Jenner's vaccinia virus as the first vaccine more than two centuries ago, which eventually led to the recent eradication of smallpox, this and other viruses may now be the basis for constructing vectors that may help us control other major scourges of mankind.

show abstract

“…Other potential bacterial vectors include Vibrio cholera, Yersinia enterocolitica, Listeria monocytogenes, Lactobacillus casei, and Streptococcus gordonii. 44 3. Protozoal vectors: One further and highly novel vector technology is based on the use of a live protozoan parasite (Eimeria) that has been genetically modified to deliver homologous or heterologous antigens to poultry.…”

Section: Bacterial Vectorsmentioning

confidence: 99%

Recent Advances in Vaccine Technologies

Francis¹

2018

Veterinary Clinics of North America: Small Animal Practice

151

View full text Add to dashboard Cite

This brief review discusses some recent advances in vaccine technologies with particular reference to their application within veterinary medicine. It highlights some of the key inactivated/killed approaches to vaccination, including natural split-product and subunit vaccines, recombinant subunit and protein vaccines, and peptide vaccines. It also covers live/attenuated vaccine strategies, including modified live marker/differentiating infected from vaccinated animals vaccines, live vector vaccines, and nucleic acid vaccines.

show abstract

Live bacterial vaccine vectors: An overview

Cited by 75 publications

References 132 publications

Salmonella typhimuriumandEscherichia colidissimilarity: Closely related bacteria with distinct metabolic profiles

Salmonella typhimuriumandEscherichia colidissimilarity: Closely related bacteria with distinct metabolic profiles

Vector-based genetically modified vaccines: Exploiting Jenner’s legacy

Recent Advances in Vaccine Technologies

Contact Info

Product

Resources

About